Compare · CHE vs REUN
CHE vs REUN
Side-by-side comparison of Chemed Corp (CHE) and Reunion Neuroscience Inc. (REUN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CHE and REUN operate in Medical/Nursing Services (Health Care), so they compete in similar markets.
- CHE carries a market cap of $6.74B.
- CHE has hit the wire 6 times in the past 4 weeks while REUN has been quiet.
- CHE has more recent analyst coverage (7 ratings vs 0 for REUN).
- Company
- Chemed Corp
- Reunion Neuroscience Inc.
- Price
- $511.70-0.54%
- $1.13+1.80%
- Market cap
- $6.74B
- -
- 1M return
- +1.30%
- -
- 1Y return
- +16.55%
- -
- Industry
- Medical/Nursing Services
- Medical/Nursing Services
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 6
- 0
- Recent ratings
- 7
- 0
Chemed Corp
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates in two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned branches and independent contractors, and franchised locations. Chemed Corporation was incorporated in 1970 and is headquartered in Cincinnati, Ohio.
Latest CHE
- Executive vice president Lee Spencer S exercised 12,099 units of Capital Stock at a strike of $445.35 and covered exercise/tax liability with 11,160 units of Capital Stock, increasing direct ownership by 7% to 14,851 units (SEC Form 4)
- Chemed To Report Third Quarter 2026 Earnings October 27, Related Conference Call To Be Held On October 28
- President and CEO Mcnamara Kevin J sold $1,026,900 worth of Capital Stock (2,000 units at $513.45), decreasing direct ownership by 3% to 66,418 units (SEC Form 4)
- Vice president Hutton Thomas C exercised 4,629 units of Capital Stock at a strike of $445.35 and covered exercise/tax liability with 4,270 units of Capital Stock, increasing direct ownership by 1% to 32,840 units (SEC Form 4)
- UBS initiated coverage on Chemed with a new price target
- President and CEO Mcnamara Kevin J sold $1,002,800 worth of Capital Stock (2,000 units at $501.40), decreasing direct ownership by 3% to 68,418 units (SEC Form 4)
- Roto-Rooter Buys Largest Franchisee Territory
- Chemed Corporation to Present at the Jefferies 2026 Healthcare Services Conference
- Executive vice president Lee Spencer S sold $541,040 worth of Capital Stock (1,000 units at $541.04), decreasing direct ownership by 7% to 13,912 units (SEC Form 4)
- President and CEO Mcnamara Kevin J sold $1,082,320 worth of Capital Stock (2,000 units at $541.16), decreasing direct ownership by 3% to 70,418 units (SEC Form 4)
Latest REUN
- SEC Form 15-12G filed by Reunion Neuroscience Inc.
- Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
- Reunion Neuroscience Completes Take-Private Setup: Delisting & Consideration Details
- SEC Form 6-K filed by Reunion Neuroscience Inc.
- SEC Form SC 13D/A filed by Reunion Neuroscience Inc. (Amendment)
- SEC Form F-10POS filed by Reunion Neuroscience Inc.
- SEC Form S-8 POS filed by Reunion Neuroscience Inc.
- SEC Form S-8 POS filed by Reunion Neuroscience Inc.
- SEC Form 25-NSE filed by Reunion Neuroscience Inc.
- Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement